한국어
Quantus

Embecta

EMBC · Nasdaq
$5.80+1.93%
2026-09-04 close

Embecta last closed at $5.80 (+1.93%) on 2026-09-04. Signals today: VCP, MACD bullish cross. Listed on Nasdaq; price, financials and dividends update daily after market close.

Loading chart…
Close
No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
277 picks
Next-day win rate
44.2%
Avg next-day
-0.28%
vs market
-0.51%p

Every new-high-plus-volume pick we actually published (US market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

B+
Overall: 건강관리 288/745 · top 39%
Factor composite · relative position in sector

PER 4.47 · PBR — — own-history percentile 81/100 · —/100

Open self-history band
PER81/100
PBR—/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Annual dividend

Split-adjusted annual DPS history and available grade axes

Annual dividend per share chart2022: $0.1520222023: $0.752024: $0.602025: $0.60$0.602025
Annual dividend (per share · split-adjusted) · as of 2025
Consistency
D
Growth
A+
Yield
A+
Safety
C+
Reference indicatorView observed cut rates

Paid 4 consecutive years · Raised 0 consecutive years · Yield 10.34% (based on 2025 payment of $0.60) · 3-year growth +58.7%

Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2025
Grey zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 1.99
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
1.99
Beneish M-Score
-3.27

No statistical flag

Sloan accrual
-8.83%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

6/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score6/9

Profitability

  • Positive ROAPass
  • Positive OCFPass
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioPass
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Balance sheetDanger

자본잠식 — 자본총계가 마이너스입니다. 부실 위험을 나타내는 사실 지표입니다.

Factual information, not investment advice.

Industry structure

USAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 124 of 543, share 0%.

124 / 5430%revenue share

Who dominates this industry?

  1. 1CVS Health14.1%
  2. 2McKesson13.6%
  3. 3Cigna9.4%
  4. 4Cardinal Health8.4%
  5. 5Centene6.2%
  6. 6Embecta0%

Concentration

DistributedCR3 37.1%
HHI 642543 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
159.97
Direction
축소
Level
넓음
Years
21

Value lens

P90/P10
24.4
Median P/B
3.02
Level
넓음
n
463

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
22.4%
Interest coverage
2.2x
Return on equity (ROE)
—

Operating margin −5pp

Tolerable
Interest coverageBase 2.2x adverse case 1.7x
Return on equity (ROE)Base — adverse case —

Revenue −15%

Tolerable
Interest coverageBase 2.2x adverse case 1.9x
Return on equity (ROE)Base — adverse case —

Interest rate +2pp

Tolerable
Interest coverageBase 2.2x adverse case 1.7x
Return on equity (ROE)Base — adverse case —

Interest coverage limit

Current margin 12.2pp

Interest coverage limit at an operating margin of 10.2%

Interest expense coverage threshold

Connections

AI-extracted related companies · for reference

🔗 See in the full market map →

Recent filings

Filings for overseas stocks are on the way. For now we cover Korean stocks only.

About Embecta
What technical signals does Embecta (EMBC) have?
Embecta current technical signals: no active technical signal.
Is Embecta a cup-and-handle pattern?
No. Embecta has no valid cup-and-handle signal right now.
What are Embecta's financials and valuation?
Embecta's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy